Pancreatic Cancer Clinical Trials in San Francisco

Showing 81-99 of 99 trials

A Study Evaluating Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Cancer

NCT01025570

The purpose of this study is to find out the effects, good and/or bad, of the combination of two drugs, gemcitabine and bosutinib, in patients with resected pancreatic cancer and whether this combination can prevent pancreatic cancer from coming back.

Pancreatic Cancer

University of California, San Francisco3 participantsStarted May 2010

San Francisco, California, United States • Salt Lake City, Utah, United States

COMPLETEDPhase 2< 1 mile

Radiation Therapy Plus Paclitaxel in Treating Patients With Nonmetastatic, Unresectable Pancreatic Cancer

NCT00003591

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of radiation therapy plus paclitaxel in treating patients who have nonmetastatic, unresectable pancreatic cancer.

Pancreatic Cancer

Radiation Therapy Oncology Group122 participantsStarted Nov 1998

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Huntsville, Alabama, United States +231 more locations

A Study Evaluating Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Cancer

Radiation Therapy Plus Paclitaxel in Treating Patients With Nonmetastatic, Unresectable Pancreatic Cancer

Pancreatic Cancer Trials in Other Cities

Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) for Pancreatic Adenocarcinoma

Gemcitabine, Cisplatin, and Bevacizumab in Treating Patients With Metastatic Pancreatic Cancer

Gemcitabine and Bevacizumab in Treating Patients With Pancreatic Cancer That Has Been Completely Removed By Surgery

Gemcitabine and Capecitabine to Treat Patients With Advanced Pancreatic and Biliary Cancers

Phase II Study to Evaluate Efficacy and Safety of RP101 in Combination With Gemcitabine

Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic Pancreatic Cancer

BMS-247550 in Treating Patients With Advanced Pancreatic Cancer

APRiCOT-P: Study of Apricoxib With Gemcitabine and Erlotinib to Treat Advanced Pancreatic Cancer

S9924 R115777 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

B-Receptor Signaling in Cardiomyopathy

Phase I/II Intratumoral DC Immunotherapy With Gemcitabine & XRT in Unresectable Pancreatic Cancer

Cyberknife Radiosurgery for Locally Advanced Pancreatic Cancer

AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy

A Study of TNFerade™ Biologic With 5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer

A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors

Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer

Vapreotide in Treating Patients Undergoing Elective Pancreatic Resection

Other Conditions in San Francisco